The development of viral hepatitis subsequent to a blood transfusion can cause serious complications for a patient. The article,"Hepatitis in Patients with Acute Nonlymphatic Leukemia" (Amer. J. of Med. (1983): 413-421) reported that in spite of careful screening for those having a hepatitis antigen, viral hepatitis occurs in 7% of blood recipients. Suppose a new treatment is believed to reduce the incidence of viral hepatitis. The treatment is given to 200 blood recipients and only 6 contract hepatitis. Does it appear that the treatment is effective? That is, is it very likely that we would observe only 6/200 contract hepatitis when 7% of the population is known to do so?